Two recent studies show the novel therapy works in people with multiple myeloma, but researchers are trying to minimize side ...

Saved from precursor B-cell acute lymphoblastic leukemia, the Nobel Prize winning CAR T-cell therapy gave Bryn Ailinger a ...

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell ...

MRD-negative status in first four heavily treated patients with "off the shelf" product ...

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...

A new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond ...

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...

In multiple myeloma, plasma cells proliferate uncontrollably in the bone marrow, disrupting the growth of healthy ...

The researchers argue that their findings, published in Scientific Reports, could help clinicians anticipate which patients ...

A breakthrough therapy is driving aggressive leukaemia into remission. Here’s what the headlines don’t tell you about life ...

Advancements in HIV/AIDS research, drug development and clinical practice since the 1980s have made it possible for people living with HIV to lead long, productive lives and keep the virus in check at ...